41 related articles for article (PubMed ID: 10823761)
1. Clinical and immunological effect of intravesical interleukin-2 on superficial bladder cancer.
Nouri AM; Hyde R; Oliver RT
Cancer Immunol Immunother; 1994 Jul; 39(1):68-70. PubMed ID: 8044829
[TBL] [Abstract][Full Text] [Related]
2. Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials.
Mahmoudpour SH; Jankowski M; Valerio L; Becker C; Espinola-Klein C; Konstantinides S; Quitzau K; Barco S
Sci Rep; 2019 May; 9(1):7145. PubMed ID: 31073219
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.
Onwumeh J; Okwundu CI; Kredo T
Cochrane Database Syst Rev; 2017 May; 5(5):CD009818. PubMed ID: 28542796
[TBL] [Abstract][Full Text] [Related]
4. IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery.
Ndhlovu LC; Sinclair E; Epling L; Tan QX; Ho T; Jha AR; Eccles-James I; Tincati C; Levy JA; Nixon DF; Hecht FM; Barbour JD
J Clin Immunol; 2010 Sep; 30(5):681-92. PubMed ID: 20571894
[TBL] [Abstract][Full Text] [Related]
5. Role of interleukin-2 in patients with HIV infection.
Pett SL; Kelleher AD; Emery S
Drugs; 2010 Jun; 70(9):1115-30. PubMed ID: 20518579
[TBL] [Abstract][Full Text] [Related]
6. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
Tavel JA; ; Babiker A; Fox L; Gey D; Lopardo G; Markowitz N; Paton N; Wentworth D; Wyman N
PLoS One; 2010 Feb; 5(2):e9334. PubMed ID: 20186278
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 therapy in patients with HIV infection.
; ; Abrams D; Lévy Y; Losso MH; Babiker A; Collins G; Cooper DA; Darbyshire J; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton JD; Phillips A; Routy JP; Tambussi G; Wentworth D
N Engl J Med; 2009 Oct; 361(16):1548-59. PubMed ID: 19828532
[TBL] [Abstract][Full Text] [Related]
8. Benefits and burdens of participation in a longitudinal clinical trial.
Lazovski J; Losso M; Krohmal B; Emanuel EJ; Grady C; Wendler D
J Empir Res Hum Res Ethics; 2009 Sep; 4(3):89-97. PubMed ID: 19754238
[TBL] [Abstract][Full Text] [Related]
9. Prospects for antisense peptide nucleic acid (PNA) therapies for HIV.
Pandey VN; Upadhyay A; Chaubey B
Expert Opin Biol Ther; 2009 Aug; 9(8):975-89. PubMed ID: 19534584
[TBL] [Abstract][Full Text] [Related]
10. Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome.
Upadhyay A; Ponzio NM; Pandey VN
Oligonucleotides; 2008 Dec; 18(4):329-35. PubMed ID: 19006449
[TBL] [Abstract][Full Text] [Related]
11. A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study.
Youle M; Emery S; Fisher M; Nelson M; Fosdick L; Janossy G; Loveday C; Sullivan A; Herzmann C; Wand H; Davey RT; Johnson MA; Tavel JA; Lane HC
PLoS Clin Trials; 2006 May; 1(1):e3. PubMed ID: 16871325
[TBL] [Abstract][Full Text] [Related]
12. Effect of pregnancy and human immunodeficiency virus infection on intracellular interleukin-2 production patterns.
Sutton MY; Holland B; Denny TN; Garcia A; Garcia Z; Stein D; Bardeguez AD
Clin Diagn Lab Immunol; 2004 Jul; 11(4):780-5. PubMed ID: 15242957
[TBL] [Abstract][Full Text] [Related]
13. Prospects for immune reconstitution in HIV-1 infection.
Imami N; Gotch F
Clin Exp Immunol; 2002 Mar; 127(3):402-11. PubMed ID: 11966755
[No Abstract] [Full Text] [Related]
14. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
16. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral chemotherapy.
Saag MS; Schooley RT
Curr Clin Top Infect Dis; 1998; 18():154-79. PubMed ID: 9779354
[No Abstract] [Full Text] [Related]
19. Ritonavir.
Lea AP; Faulds D
Drugs; 1996 Oct; 52(4):541-6; discussion 547-8. PubMed ID: 8891466
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
